News • Prevention improvement

Bowel cancer: most cases diagnosed outside of screening programmes

More than 70 percent of patients with bowel cancer are not diagnosed using official screening programmes meaning diagnoses are often made late, when the cancer is at an advanced stage, according to new research from the University of Surrey.

Photo

Image source: Adobe Stock/SciePro

Embarrassment is the biggest reason for avoiding screening. 

In a paper published by the Journal of Medical Screening, researchers investigated the number of bowel cancers diagnosed outside of traditional screening programmes and the reasons why this may be. Screening for bowel cancer consists of a faecal immunochemical test and involves taking a sample of faeces to be examined for traces of blood. 

Dr Robert Kerrison, Lecturer in Cancer Care at the University of Surrey, said: “Bowel cancer is one of the biggest cancer killers in England. When diagnosed early, the disease is highly treatable. It is vital, therefore, that it is caught early, if we are to reduce of the number of deaths from bowel cancer. Screening is one of the best and most effective ways of detecting cancer early, as it allows us to test for the disease, before symptoms develop and I would urge those eligible to utilize the screening kits which are automatically sent to our homes for samples to be provided. It is very concerning that the majority of patients are receiving diagnoses via other routes, often at a time when the cancer is at a more advanced stage, as our research shows. There are a number of different reasons why people don’t take part in screening. One of the biggest reasons is that people often feel embarrassed when it comes to poo (the “poo taboo” as Deborah James describes it). We need to normalize this and help people understand the importance of screening, as it undoubtedly saves lives.”

Analysing data from over 400 patients with bowel cancer at St. Mark’s Hospital in Harrow, all of whom were eligible to take part in screening at the time of their diagnosis, the researchers found that over 60 percent of those not diagnosed through screening had never taken part in official programmes, and a smaller proportion (nearly 10 percent) had not kept up to date with regular screening. Those who had not kept up to date were more likely to be diagnosed with metastatic disease, when cancer spreads to a different part of the body and is more difficult to treat. 

It was also uncovered that a considerable proportion of those who regularly participated in screening had received a normal or weak positive result that did not require further investigation and then had a subsequent positive diagnosis for the disease. 

The research was conducted in collaboration with St Mark’s Hospital Harrow and University College London.


Source: University of Surrey

09.06.2022

Read all latest stories

Related articles

Photo

News • Automated adenoma analysis

AI finds more precancerous polyps than traditional colonoscopy

Colonoscopies performed with AI support may yield an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data.

Photo

News • Cytosponge research

‘Pill on a string’ test could transform oesophageal cancer diagnosis

A ‘pill on a string’ test can identify ten times more people with Barrett’s oesophagus than the usual GP route, a new study shows. The test, which can be carried out by a nurse in a GP surgery,…

Photo

News • CancerSEEK

Single blood test screens for 8 cancer types

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer. The test, called CancerSEEK, is…

Related products

Associates of Cape Cod – Fungitell STAT Assay

Identification/Susceptibility

Associates of Cape Cod – Fungitell STAT Assay

Associates of Cape Cod Europe GmbH
Hologic – SuperSonic Mach 30

Ultrasound

Hologic – SuperSonic Mach 30

Hologic, Inc.
Image Information Systems – iQ-View

Reading

Image Information Systems – iQ-View

IMAGE Information Systems Europe GmbH
Lifotronic - FA-160 Immunofluorescence Analyzer

Immunoassays

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Subscribe to Newsletter